Compare Regeneron Pharmaceuticals Inc (REGN) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Tidewater Inc trades at $86.94 (market cap $4.15B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.4× Tidewater Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Tidewater Inc for 25 Days on average.
| REGN | TDW | |
|---|---|---|
Market Cap | $76.40B | $4.15B |
Volume | 626,381 | 662,838 |
Sector | Health | Energy |
52-Week High | $852.03 | $100.61 |
52-Week Low | $557.73 | $47.29 |
Typical Hold Time | 107 Days | 25 Days |
Enterprise Value | $71.12B | $4.19B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Tidewater (TDW) trades at $83.40, up 1.62% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 18.34% net margins and 19.49% ROE, though recent Q2 2026 earnings missed expectations. Recent developments include the completion of Wilson Sons Ultratug acquisition in August 2026 and significant institutional buying from BlackRock.
TDW presents a mixed outlook with solid fundamentals but recent earnings volatility. The 26% upside to consensus price target of $105.50 offers potential, though execution risks from integration challenges and competitive pressures warrant caution. Institutional accumulation and bullish technicals support near-term strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
